Regenerative care uses blood or bone marrow but doesn't rebuild a hip

PRP starts with blood taken from your arm

Clinic staff draw your blood and spin it. The spinning separates a part rich in platelets. That prepared part is called concentrated PRP. Clinics don't always prepare it alike.

The platelets release natural substances near the sore tissue. Those substances may help ease local soreness. They don't become pieces of new cartilage.

You'll still value less soreness in daily life. Yet relief doesn't prove that tissue grew. Ask what you may notice while walking or sleeping.

Worn cartilage doesn't mend like skin

Joint cartilage coats the bone ends with smooth tissue. That tissue lets the bones glide. Little blood reaches it, so broad wear heals poorly. Your weight presses on it whenever you stand.

Soreness can ease even when cartilage hasn't changed. Stronger muscles won't rebuild that smooth tissue. They'll share some work with the joint. Your pain can drop while an X-ray stays unchanged.

Be careful when someone promises new cartilage. Ask whether a hip image showed new tissue. Knee research can't predict your hip result.

The exam must find where the pain starts

Care near a tendon isn't the same as joint care. A tendon is a strong cord between muscle and bone. Your exam must find which area hurts. Hip care won't fix pain coming from your back.

Tell the clinician when soreness starts. Mention sitting, stairs, sleep, and walking. Don't leave out numbness or a recent fall.

At home, choose one task that always hurts. Note how long you can do it. Bring that note to your visit. After clinic staff examine the sore area, QC Kinetix discusses regenerative treatment options prepared from your blood or bone marrow.

Sources

1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

   Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

2. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product.

   Tan AR, et al. — Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.16-0271.

3. The phase II trial of lorecivivint (SM04690), an intra-articular CLK2/DYRK1A inhibitor and Wnt-pathway modulator, is the reference for how a genuine disease-modifying osteoarthritis DRUG is developed - defined molecule, defined target, dose-ranging, radiographic endpoints - which is the standard against which an unstandardised autologous injectate should be read.

   Yazici Y, et al. — Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.. Arthritis & rheumatology (Hoboken, N.J.), 2020. DOI: 10.1002/art.41315.

4. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another.

   Yoshioka T, et al. — The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.. The American journal of sports medicine, 2024. DOI: 10.1177/03635465241263073.

5. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.